Evidence map›Paper›PMID 41833878›Full record

ArticleEuropean journal of pharmacology2026

UC2288 decreases the viability and metastatic activity of human Uveal melanoma cells via activating the AMPK/eIF2/ATF4 ER stress axis.

Janney Z Wang, Yihe Niu, Xue Zhu, Sophie Theresa Gerstlauer, Nguyen Huong Que Hiep Dang, Ling Zhu, Jin-Jian Lu, Hong Zhu, Ke Wang, Svetlana Cherepanoff and 6 more

Abstract read
In one paragraph

Article in European journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Janney Z WangMolecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.
Yihe NiuMolecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.
Xue ZhuKey Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu Province, 214063, China.
Sophie Theresa GerstlauerMolecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Institute of Molecular Medicine, Faculty of Medicine, Martin Luther University, Halle (Saale), 06112, Germany.
Nguyen Huong Que Hiep DangMolecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.
Ling ZhuSave Sight Institute, The University of Sydney, Sydney, NSW, 2006, Australia.
Jin-Jian LuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Hong ZhuZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang Province, 310058, China.
Ke WangKey Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu Province, 214063, China.
Svetlana CherepanoffSydPath, Department of Anatomical Pathology, St Vincent's Hospital, Darlinghurst, NSW, 2010, Australia.
R Max ConwaySave Sight Institute, The University of Sydney, Sydney, NSW, 2006, Australia; Ocular Oncology Unit, Sydney Eye Hospital and The Kinghorn Cancer Centre, Sydney, NSW, 2006, Australia.
Michele C MadiganSave Sight Institute, The University of Sydney, Sydney, NSW, 2006, Australia; School of Optometry and Vision Science, UNSW Sydney, NSW, 2052, Australia.
Christophe MorisseauDepartment of Entomology and Nematology, And UCD Comprehensive Cancer Center, University of California, Davis, CA, 95616, USA.
Michael MurrayMolecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.
Bruce D HammockDepartment of Entomology and Nematology, And UCD Comprehensive Cancer Center, University of California, Davis, CA, 95616, USA.
Fanfan ZhouMolecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia. Electronic address: fanfan.zhou@sydney.edu.au.

Funding

UC Davis CounterACT Center of Excellence: Developing Therapeutic Strategies for Mitigating the Chronic Neurological Consequences of Acute Organophosphate IntoxicationU54NS127758 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Amy R. Brooks-Kayal, Pamela J Lein · 2022 to 2026
$17.2M
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
$5.8M
NIEHS NIH HHS R35 ES030443NINDS NIH HHS U54 NS127758
6 · The paper itself

Abstract

Uveal melanoma (UM) is the primary intraocular malignancy in adults and has an extremely poor prognosis due to a high rate of metastasis. Because current drug options are generally ineffective, there is an urgent need for new agents with anti-UM efficacy. The phenylcyclohexyl-urea UC2288 was investigated in in vitro, ex vivo and in vivo UM models. The anti-cancer actions of UC2288 were evaluated using cell viability and cell death assays. Tumour migration, invasion and reproductive cell growth assays were used to assess the anti-metastatic potential of UC2288. Such effects were corroborated in primary cultures derived from patient tumours and in vivo in a UM cell xenograft mouse model. UC2288 decreased UM cell proliferation in conventional and 3-dimensional cell culture by disrupting cell cycle progression and modulating cyclin expression. UC2288 also targeted the mitochondrion and increased the production of reactive oxygen species, which promoted necrotic cell death. In mechanistic studies, UC2288 activated AMPK and downstream eIF2/ATF pathways of ER stress and autophagy in UM cells. UC2288 also impaired UM cell migration, invasion and reproductive growth, which is consistent with anti-metastatic activity. These findings were replicated in vivo in a UM cell xenograft model. Taken together, UC2288 represents a promising candidate for further development that targets UM tumours with favourable anti-cancer effects.

Indexed as

Activating Transcription Factor 4AMP-Activated Protein KinasesAntineoplastic AgentsEndoplasmic Reticulum StressEukaryotic Initiation Factor-2MelanomaUveal NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleHumansMiceMice, NudeActivating Transcription Factor 4AMP-Activated Protein KinasesAntineoplastic AgentsATF4 protein, humanEukaryotic Initiation Factor-2Reactive Oxygen SpeciesAnti-cancerAnti-metastaticER stressUC2288Uveal melanoma

Identifiers

PMID41833878
PMCPMC13182895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.